News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
314,991 Results
Type
Article (19247)
Company Profile (153)
Press Release (295591)
Multimedia
Podcasts (52)
Webinars (2)
Section
Business (84364)
Career Advice (110)
Deals (15353)
Drug Delivery (56)
Drug Development (57268)
Employer Resources (30)
FDA (9696)
Job Trends (6417)
News (164041)
Policy (14020)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (5)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (1087)
Academic (1)
Accelerated approval (6)
Adcomms (20)
Allergies (49)
Alliances (24646)
ALS (70)
Alzheimer's disease (941)
Antibody-drug conjugate (ADC) (107)
Approvals (9712)
Artificial intelligence (130)
Autoimmune disease (20)
Automation (7)
Bankruptcy (90)
Best Places to Work (5827)
BIOSECURE Act (12)
Biosimilars (64)
Biotechnology (118)
Bladder cancer (57)
Brain cancer (25)
Breast cancer (227)
Cancer (1795)
Cardiovascular disease (131)
Career advice (99)
Career pathing (3)
CAR-T (164)
Cell therapy (455)
Cervical cancer (11)
Clinical research (47689)
Collaboration (601)
Compensation (266)
Complete response letters (21)
COVID-19 (1143)
CRISPR (39)
C-suite (152)
Cystic fibrosis (91)
Data (1653)
Denatured (9)
Depression (31)
Diabetes (164)
Diagnostics (2235)
Digital health (8)
Diversity, equity & inclusion (6)
Drug discovery (85)
Drug pricing (43)
Drug shortages (20)
Duchenne muscular dystrophy (88)
Earnings (32522)
Editorial (16)
Employer branding (5)
Employer resources (28)
Events (49838)
Executive appointments (428)
FDA (10568)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (452)
Gene editing (94)
Generative AI (11)
Gene therapy (333)
GLP-1 (463)
Government (1634)
Grass and pollen (2)
Guidances (24)
Healthcare (8949)
Huntington's disease (19)
IgA nephropathy (23)
Immunology and inflammation (96)
Indications (22)
Infectious disease (1210)
Inflammatory bowel disease (103)
Inflation Reduction Act (3)
Influenza (25)
Intellectual property (58)
Interviews (11)
IPO (7705)
IRA (15)
Job creations (933)
Job search strategy (94)
Kidney cancer (6)
Labor market (9)
Layoffs (218)
Leadership (1)
Legal (2125)
Liver cancer (57)
Lung cancer (269)
Lymphoma (135)
Machine learning (2)
Management (7)
Manufacturing (196)
MASH (53)
Medical device (5149)
Medtech (5153)
Mergers & acquisitions (8030)
Metabolic disorders (472)
Multiple sclerosis (61)
NASH (14)
Neurodegenerative disease (71)
Neuropsychiatric disorders (22)
Neuroscience (1355)
NextGen: Class of 2025 (2453)
Non-profit (1370)
Northern California (1713)
Now hiring (9)
Obesity (258)
Opinion (95)
Ovarian cancer (62)
Pain (59)
Pancreatic cancer (63)
Parkinson's disease (125)
Partnered (11)
Patents (135)
Patient recruitment (81)
Peanut (29)
People (23881)
Pharmaceutical (33)
Pharmacy benefit managers (3)
Phase I (14717)
Phase II (21304)
Phase III (16238)
Pipeline (865)
Policy (53)
Postmarket research (1693)
Preclinical (5525)
Press Release (48)
Prostate cancer (85)
Psychedelics (35)
Radiopharmaceuticals (191)
Rare diseases (346)
Real estate (1980)
Recruiting (14)
Regulatory (11697)
Reports (19)
Research institute (1271)
Resumes & cover letters (8)
Rett syndrome (4)
RNA editing (2)
RSV (15)
Schizophrenia (53)
Series A (87)
Series B (52)
Service/supplier (4)
Sickle cell disease (47)
Southern California (1324)
Special edition (9)
Spinal muscular atrophy (126)
Sponsored (16)
Startups (1771)
Stomach cancer (14)
Supply chain (36)
Tariffs (7)
The Weekly (42)
United States (13911)
Vaccines (252)
Venture capitalists (23)
Weight loss (165)
Women's health (12)
Worklife (1)
Date
Today (7)
Last 7 days (294)
Last 30 days (1581)
Last 365 days (21742)
2025 (6117)
2024 (22877)
2023 (24968)
2022 (31433)
2021 (32547)
2020 (28202)
2019 (20583)
2018 (15297)
2017 (16613)
2016 (14530)
2015 (17028)
2014 (11717)
2013 (9002)
2012 (9249)
2011 (9418)
2010 (8515)
Location
Africa (201)
Alabama (31)
Alaska (3)
Arizona (64)
Arkansas (5)
Asia (30347)
Australia (4407)
California (3701)
Canada (991)
China (433)
Colorado (130)
Connecticut (171)
Delaware (86)
Europe (47007)
Florida (496)
Georgia (116)
Idaho (20)
Illinois (242)
India (22)
Indiana (156)
Iowa (2)
Japan (133)
Kansas (42)
Kentucky (19)
Louisiana (4)
Maine (10)
Maryland (520)
Massachusetts (3047)
Michigan (59)
Minnesota (213)
Missouri (58)
Montana (6)
Nebraska (4)
Nevada (33)
New Hampshire (30)
New Jersey (1168)
New Mexico (14)
New York (1071)
North Carolina (644)
North Dakota (7)
Northern California (1713)
Ohio (123)
Oklahoma (6)
Oregon (15)
Pennsylvania (878)
Puerto Rico (2)
Rhode Island (9)
South America (290)
South Carolina (3)
Southern California (1324)
Tennessee (28)
Texas (520)
Utah (68)
Virginia (92)
Washington D.C. (27)
Washington State (396)
Wisconsin (27)
314,991 Results for "immunovative therapies ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Autoimmune disease
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.
March 19, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Immunovant Announces $450 Million Private Placement
January 14, 2025
·
3 min read
Press Releases
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
March 19, 2025
·
9 min read
Press Releases
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
February 6, 2025
·
11 min read
Press Releases
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)
March 11, 2025
·
3 min read
Press Releases
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
March 18, 2025
·
1 min read
Press Releases
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers
February 25, 2025
·
3 min read
Business
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.
May 29, 2024
·
14 min read
Press Releases
Immunovant Provides Update on Graves’ Disease Development Program
September 9, 2024
·
6 min read
Policy
Immunovant Awarded U.S. Patent for IMVT-1402
Immunovant, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor.
March 12, 2024
·
4 min read
1 of 31,500
Next
